BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 23393332)

  • 1. Intraoperative imaging of metastatic lymph nodes using a fluorophore-conjugated antibody in a HER2/neu-expressing orthotopic breast cancer mouse model.
    Wu J; Ma R; Cao H; Wang Z; Jing C; Sun Y; Zhang Y; Yang Z; Hoffman RM; Tang J
    Anticancer Res; 2013 Feb; 33(2):419-24. PubMed ID: 23393332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu.
    Koyama Y; Hama Y; Urano Y; Nguyen DM; Choyke PL; Kobayashi H
    Clin Cancer Res; 2007 May; 13(10):2936-45. PubMed ID: 17504994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
    Aoyama K; Kamio T; Nishikawa T; Kameoka S
    Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
    Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
    J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.
    Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G
    J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT; Lee TW; Lo JM
    Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Targeted detecting HER2 expression with recombinant anti HER2 ScFv-GFP fusion antibody].
    Gao G; Chen C; Yang Y; Yang H; Wang J; Zheng Y; Huang Q; Hu X
    Sheng Wu Gong Cheng Xue Bao; 2012 Aug; 28(8):1002-14. PubMed ID: 23185900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
    Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
    J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
    Pommier SJ; Quan GG; Christante D; Muller P; Newell AE; Olson SB; Diggs B; Muldoon L; Neuwelt E; Pommier RF
    Ann Surg Oncol; 2010 Feb; 17(2):613-23. PubMed ID: 19838757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice.
    Penichet ML; Challita PM; Shin SU; Sampogna SL; Rosenblatt JD; Morrison SL
    Lab Anim Sci; 1999 Apr; 49(2):179-88. PubMed ID: 10331548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multilayered, core/shell nanoprobes based on magnetic ferric oxide particles and quantum dots for multimodality imaging of breast cancer tumors.
    Ma Q; Nakane Y; Mori Y; Hasegawa M; Yoshioka Y; Watanabe TM; Gonda K; Ohuchi N; Jin T
    Biomaterials; 2012 Nov; 33(33):8486-94. PubMed ID: 22906608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
    Brück P; Vilches Cisneros N; Ramos López E; Barboza Quintana O; Ancer Rodríguez J; Flores Gutiérrez JP
    Ginecol Obstet Mex; 2006 Oct; 74(10):516-22. PubMed ID: 21961357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
    Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
    Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer.
    Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):78-83. PubMed ID: 10482197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer.
    Cabioglu N; Yazici MS; Arun B; Broglio KR; Hortobagyi GN; Price JE; Sahin A
    Clin Cancer Res; 2005 Aug; 11(16):5686-93. PubMed ID: 16115904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2-neu positivity in patients with small and node-negative breast cancer (pT1a,b,N0,M0): a high risk group?
    Chavez-MacGregor M; Gonzalez-Angulo AM
    Clin Adv Hematol Oncol; 2009 Sep; 7(9):591-8. PubMed ID: 20020671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of HER2/neu in primary and metastatic breast cancer.
    Tuziak T; Olszewski WP; Olszewski W; Pieńkowski T
    Pol J Pathol; 2001; 52(1-2):21-6. PubMed ID: 11505677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.